Literature DB >> 16729976

Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).

Nazli Maki1, Saibal Dey.   

Abstract

The drug-transport function of the human P-glycoprotein (Pgp or ABCB1) is inhibited by a number of structurally unrelated compounds, known as modulators or reversing agents. Among them, the thioxanthene derivative flupentixol inhibits Pgp-mediated drug transport by an allosteric mechanism. Unlike most other Pgp modulators, the cis isomer of flupentixol [cis-(Z)-flupentixol] facilitates interaction of Pgp with its transport-substrate [125I]iodoarylazidoprazosin (or [125I]IAAP), yet inhibits transport. In this study, we show that the flupentixol site acts as a common site of interaction for the tricyclic ring-containing modulators thioxanthenes and phenothiazines. The allosteric stimulation of [125I]IAAP binding to Pgp occurs independent of the phosphorylation status of the transporter. Stimulation is retained in purified Pgp reconstituted into proteoliposomes, suggesting no involvement of any other cellular protein in the phenomenon. However, perturbation of the lipid environment of the reconstituted Pgp by nonionic detergent octylglucoside abolishes stimulation by cis-(Z)-flupentixol of [125I]IAAP binding. Extensive trypsin digestion of the [125I]IAAP-labeled Pgp generates a 5.5 kDa fragment with 80% of the stimulated level of labeling associated with it. Sensitivity to inhibition by transport-substrate vinblastine and competitive modulator cyclosporin A suggests that the elevated level of [125I]IAAP binding to the fragment represents a functionally relevant interaction with the substrate site of Pgp. In summary, we demonstrate that allosteric modulation by cis-(Z)-flupentixol is mediated through its interaction with Pgp at a site specific for tricyclic ring-containing Pgp modulators of thioxanthene and phenothiazine backbone, independent of other cellular components and the phosphorylation status of the protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16729976     DOI: 10.1016/j.bcp.2006.04.008

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.

Authors:  Debjani Mandal; Karobi Moitra; Debabrata Ghosh; Di Xia; Saibal Dey
Journal:  Biochemistry       Date:  2012-03-22       Impact factor: 3.162

Review 2.  Targeting efflux pumps to overcome antifungal drug resistance.

Authors:  Ann R Holmes; Tony S Cardno; J Jacob Strouse; Irena Ivnitski-Steele; Mikhail V Keniya; Kurt Lackovic; Brian C Monk; Larry A Sklar; Richard D Cannon
Journal:  Future Med Chem       Date:  2016-07-27       Impact factor: 3.808

3.  Folding correction of ABC-transporter ABCB1 by pharmacological chaperones: a mechanistic concept.

Authors:  Matthias Spork; Muhammad Imran Sohail; Diethart Schmid; Gerhard F Ecker; Michael Freissmuth; Peter Chiba; Thomas Stockner
Journal:  Pharmacol Res Perspect       Date:  2017-05-26

4.  Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action.

Authors:  Qian Liu; Pei Cai; Siwei Guo; Jiangong Shi; Hua Sun
Journal:  Aging (Albany NY)       Date:  2020-02-28       Impact factor: 5.682

5.  Generating inhibitors of P-glycoprotein: where to, now?

Authors:  Emily Crowley; Christopher A McDevitt; Richard Callaghan
Journal:  Methods Mol Biol       Date:  2010
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.